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Abstract: Lung cancer is the leading cause of mortality in the United States. Non-small cell 
lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most NSCLC 
patients present with loco-regionally advanced or metastatic disease where response rates are 
low and median overall survival approximates 8 to 10 months. Chemotherapy is the mainstay 
of treatment for NSCLC patients with metastatic disease. Epidermal growth factor receptor 
(EGFR) and family of receptors play a critical role in lung cancer tumorigenesis. Cetuximab, 
a monoclonal antibody that binds the EGFR, has demonstrated preclinical and clinical activity 
against NSCLC. This review focuses on the use of cetuximab in NSCLC.
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Introduction
Lung cancer is the leading cause of cancer related mortality in the United States.1,2 
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung can-
cer cases and encompasses different histologies including squamous cell carcinoma, 
large cell carcinoma and adenocarcinoma with or without bronchioalveolar features.
NSCLC is staged according to the TNM (tumor, node, and metastasis) system.3,4 Early 
stage lung cancer represents a minority of cases and is often curable with surgery with or 
without adjuvant chemotherapy. Adjuvant chemotherapy consisting of a cisplatin-based 
doublet is associated with improved survival in patients with resected stage II–IIIA 
lung cancer.5–9 Some patients with stage IB lung cancer may also derive a benefit 
from chemotherapy.10 The optimal management of unresectable stage IIIA NSCLC is 
controversial and depends on the nodal status and tumor size and location.11
A sizeable majority of patients with NSCLC present with distant metastases 
where chemotherapy is the mainstay of treatment. In the 1980s, doxorubicin- and 
cyclophosphamide-containing regimens were used without substantially improving 
survival.12–14 Subsequently single-agent chemotherapy with paclitaxel, gemcitabine, 
and vinorelbine was compared to best supportive care, suggesting a favorable sur-
vival trend for chemotherapy with these agents.15–17 Based on these encouraging 
results, trials of combination chemotherapy with cisplatin and the previously used 
single agents were conducted and showed a further improvement in overall and dis-
ease-free survival.18,19 These trials established platinum doublet as the cornerstone 
of chemotherapy for advanced NSCLC. Equivalence of different platinum doublet 
combinations was demonstrated in randomized phase III studies.20–22 In a recent 
landmark trial, addition of bevacizumab, an antibody against the vascular endothelial OncoTargets and Therapy 2009:2 252
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growth factor, to carboplatin and paclitaxel was associated 
with improved overall and progression-free survival (PFS) in 
patients with non-squamous histologies.23 This was the first 
trial to show an improvement in survival with the use of tar-
geted agents in addition to standard chemotherapy in patients 
with NSCLC. In another trial, addition of bevacizumab to 
cisplatin and gemcitabine was associated with significant 
improvement in PFS and response rate.24
A more recent trial compared cisplatin and pemetrexed to 
cisplatin and gemcitabine, with similar overall survival and 
somewhat better tolerability for the pemetrexed-containing 
arm. However, in a prespecified subset analysis, the cisplatin 
and pemetrexed arm demonstrated statistically significant 
improvement in survival for the adenocarcinoma and large 
cell carcinoma histologies.25 Conversely, the cisplatin and 
gemcitabine arm proved to be superior for the squamous 
cell cancers of the lung.
Currently, palliative chemotherapy is the standard of care 
for patients with metastatic NSCLC. First-line treatment 
involves administration of 4 to 6 cycles of platinum-containing 
doublet chemotherapy26,27 with or without bevacizumab.23,24 
The addition of bevacizumab and pemetrexed in specific 
subsets of NSCLC have resulted in modest improvements in 
survival, however these have only been seen in select patient 
populations. Newer therapies are therefore desperately 
needed to improve outcomes in the greater majority of 
patients with NSCLC.
Epidermal growth factor receptor
The epidermal growth factor receptor (EGFR) is one of a 
family of receptors that has growth promoting effects in 
NSCLC. EGFR is overexpressed in about 40% to 80% of 
NSCLC.28 Downstream signaling by the activated EGFR can 
be abrogated by small molecule inhibitors, such as erlotinib 
and gefitinib or by monoclonal antibodies directed towards 
the extracellular domain of EGFR, such as cetuximab.
The EGFR (ErbB1) is a transmembrane receptor of the 
tyrosine kinase (TK) family of receptors. It is a 170 kDa pro-
tein and has 3 closely related members, HER2/Neu (ErbB2), 
HER3 (ErbB3), and HER4 (ErbB4). All members, except 
for HER2/Neu, have an extracellular ligand binding domain. 
Additionally all members, except HER3, are equipped with 
an intracellular domain with TK activity. Ligand binding 
results in receptor homodimerization or heterodimerization 
and consequent phosphorylation of the TK domain. EGF and 
transforming growth factor (TGF) alpha appear to be key 
ligands, but others, like epiregulin, betacellulin, epigen, and 
amphiregulin, have been shown to be relevant predictors of 
response and resistance.29,30 A series of downstream signals 
lead to tumor proliferation, angiogenesis, and inhibition of 
apoptosis by the Ras-Raf-Mitogen activated protein kinase 
(MAPK) and phosphatidylinositol-3-kinase (PI3)-Akt path-
ways.31,32 Interaction between EGFR expression and STAT 3 
(signal transducers and activators of transcription 3) has also 
been shown to be important in gene transcription.33–35
Small-molecule EGFR TK inhibitors (TKIs) are 
competetive inhibitors and bind reversibly to the intracel-
lular catalytic domain of EGFR tyrosine kinase and, thus, 
inhibit EGFR autophosphorylation and downstream signal-
ing. Anti-EGFR monoclonal antibodies, on the other hand, 
recognize EGFR exclusively and are therefore highly selec-
tive for this receptor. In addition, various small-molecule 
EGFR TKIs can block different growth factor receptor 
TKs, including other members of the EGFR family, while 
antibodies are fairly specific. Erlotinib is approved for 
second- or third-line treatment in chemotherapy-resistant 
advanced NSCLC based on superior overall survival results 
from a phase III randomized study.36 Females, non-smokers, 
Asian patients, and patients with adenocarcinoma and EGFR 
mutations derive the maximum benefit when treated with 
small molecule TKIs.37 In combination with chemotherapy, 
erlotinib did not confer any additional benefit over chemo-
therapy alone in two separate phase III trials.38,39 Therefore, 
at this point erlotinib is used in patients with evidence of 
recurrent disease. A study to evaluate the role of this agent 
in the maintenance setting is ongoing. Also, the potential use 
of this agent in the front-line setting in patients with activat-
ing EGFR mutations is under investigation. This review will 
focus on pharmacology, safety, efficacy, and future directions 
of the use of cetuximab in NSCLC.
Pharmacology of cetuximab
Murine antibody to EGFR, mAb225, was initially developed 
from a panel of anti-EGFR antibodies based upon receptor 
affinity and efficacy.40 All patients treated with this antibody 
in a phase I study developed human antimurine antibodies. 
Therefore a chimeric human–mouse version of mAb225 
(C225, cetuximab) was produced. Cloned heavy and light 
chains of mAb225 were adapted for expression with a 
constant region of the human kappa light chain and human 
gamma 1 heavy chain. This antibody, cetuximab, binds to 
EGFR with higher affinity than its murine counterpart.41–44
Initial phase I trials established 400 to 500 mg/m2 intrave-
nously (iv) as loading dose to be followed by 250 mg/m2 iv 
weekly based on adverse effect profile and pharmacokinetic 
parameters.42,45,46OncoTargets and Therapy 2009:2 253
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Epithelial cancers are often associated with activation of 
growth factor receptors of the EGFR family. Anti-EGFR anti-
bodies recognize EGFR exclusively and are therefore highly 
selective for this receptor. The EGFR has an extracellular 
and intracellular domain. The extracellular domain has 
4 subunits, which exist in a compact, tethered auto-inhibited 
condition in the absence of a ligand.47 Cetuximab prevents 
ligand binding to EGFR, inhibits receptor dimerization, and 
therefore blocks downstream signaling. Cetuximab binds 
to domain III of the receptor and sterically blocks access to 
the key ligand binding region of the receptor. There is also 
evidence that, in the presence of cetuximab, the EGFR extra-
cellular component cannot adopt the extended dimerization 
configuration preventing its activation.47 It binds with higher 
affinity than its endogenous ligands and promotes receptor 
internalization and degradation.48 By promoting receptor 
removal from the cell surface, cetuximab also reduces the 
active pool of protein available to signal.49
EGFR pathway is important in proliferation, metastasis, 
cancer cell invasion, and angiogenesis.50 Blockade of EGFR 
pathway by cetuximab leads to inhibition of cancer cell pro-
liferation (blockade of cell cycle progression and G1 arrest 
through an increase in p27kip1 inhibitor of cyclin-dependent 
kinases),51–53 inhibition of tumor-induced angiogenesis by 
blockade of production of angiogenic factors (transforming 
growth factor alpha, VEGF, IL8, basic FGF), inhibition 
of invasion and metastasis, and potentiation of antitumor 
activity of cytotoxic drugs and radiation therapy.44,54 There 
is also evidence of IgG1-mediated antibody directed cell 
mediated cytotxicity (ADCC).55
In preclinical animal models, cetuximab and other 
epidermal growth factor receptor antagonists have been shown 
to be synergistic with cisplatin56,57 and paclitaxel.58,59 In a 
preclinical study, the efficacy of combination of cetuximab 
and paclitaxel was evaluated for treating human transitional 
cell carcinoma (TCC) of the urinary bladder of nude mice.59 
Paclitaxel demonstrated significant antitumor activity and 
the extent of paclitaxel-induced apoptosis was enhanced 
in the presence of reduced Raf-1 activity.60 Cetuximab 
downregulates Raf-1 activity, and presumably by this 
mechanism cetuximab enhances the antiproliferative and 
apoptotic effects of paclitaxel in a dose-dependent manner in 
vitro. A second hypothesis for this synergy is that treatment 
with paclitaxel may upregulate EGFR receptors in tumor cells, 
making cells more susceptible to anti-EGFR therapies.
Resistance eventually emerges in most tumors initially 
susceptible to anti-EGFR approaches. Various mechanisms 
of resistance have been documented in preclinical and 
clinical models. Active EGFR signaling may lead to resistance 
by upregulation of ATP-binding cassette (ABC) proteins. 
ABC proteins confer resistance by actively pumping drugs 
out of the cancer cell. In breast adenocarcinoma cell lines, 
activation of the EGFR pathway is linked to activation of the 
multidrug resistance transporter family.61 EGFR resistance 
may also be due to mutations in the receptor protein itself. 
The T790M mutation substitutes methionine for a threonine 
residue, leading to resistance by reducing affinity to small-
molecule TKIs and increasing competitive ATP binding.62 
This mutation is seen in about 50% of patients demonstrating 
acquired resistance to TKIs. Heterodimerization with other 
HER partners may represent an alternative mechanism 
of resistance. Cancer cells expressing EGFR and ErbB2 
are nonresponsive to inhibitors targeting one of these two 
proteins.63 Similarly, overexpression of ErbB3 also confers 
resistance to EGFR inhibitors.64 Expression of hepatocyte 
growth factor and c-Met dependent signaling is also an 
alternative pathway for signaling conferring resistance (seen 
in approximately 20% of patients with acquired resistance to 
TKIs).65 Finally, interactions between EGFR and the insulin 
growth factor receptor (IGF-1R) can provide resistance to 
agents targeting EGFR.66
Although the above mechanisms are mainly responsible 
for resistance to TKIs, downstream activating mutations 
of the core effector pathway play a central role in mediat-
ing resistance to agents targeted both intracellularly and 
extracellularly. The most validated downstream resistance 
mechanism is the KRAS pathway. Mutant KRAS exists in 
the activated state and constitutively activates downstream 
signals of cell proliferation, motility and metastasis, and 
survival. Mutant KRAS (found in approximately 15% to 30% 
of patients with NSCLC) is associated with worse survival 
in response to EGFR antibodies in colorectal cancers.67–69 
In NSCLC, a retrospective analysis of tumor samples from 
erlotinib or gefitinib sensitive patients revealed that KRAS 
mutation was associated with resistance to either therapy.70 
Clinical data from the FLEX study71 do not support the 
hypothesis that KRAS mutation status is predictive for 
cetuximab efficacy when combined with first-line chemo-
therapy in advanced NSCLC, whereas early acne-like rash 
of any grade appears to be associated with better outcome 
in patients treated with cetuximab.72
EGFR expression by immunohistochemistry and 
amplification by fluorescence in situ hybridization (FISH) 
have been evaluated as potential markers for response to 
EGFR targeted agents.73,74 These have not been associated 
with differential outcomes in response to EGFR TKIs. OncoTargets and Therapy 2009:2 254
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However, in a recent study, increase in EGFR gene copy 
number by FISH (4 or more gene copies per cell in 40% 
of the cells or gene amplification) was shown to predict for 
survival in advanced-stage NSCLC receiving sequential or 
concurrent chemotherapy (paclitaxel plus carboplatin) with 
cetuximab. Larger, prospective confirmatory studies are 
required for confirmation of this observation.75
Clinical efficacy in first-line setting
NSCLCs often overexpress EGFR, making cetuximab an 
attractive targeted agent for use in these patients.76 It has been 
used in several trials in the first-line setting in stage IIIb/IV 
NSCLC (Table 1).
In a multicenter phase I/II study, Thienelt et al used 
cetuximab in the first-line setting in combination with 
carboplatin at an area under the curve (AUC) of 6 and 
paclitaxel (225 mg/m2) in patients with advanced stage 
NSCLC.77 Cetuximab was administered iv at 400 mg/m2, 
1 week before paclitaxel and carboplatin, then weekly at 
250 mg/m2 (standard dosing). Patients had to have EGFR pos-
itive disease by immunohistochemistry (IHC), performance 
status (PS) of 0 to 2, and measurable disease. The regimen 
was continued until disease progression or intolerable toxic-
ity. Patients who did not tolerate chemotherapy because of 
toxicity could continue on weekly cetuximab monotherapy 
until disease progression or unacceptable toxicity. Thirty-one 
patients were treated and an objective response was observed 
in 8 patients (26%). At a median follow-up of 19 months, 
the median time to progression (TTP) was 5 months, median 
survival was 11 months, and the 1- and 2-year survival rates 
Table 1 Trials evaluating use of cetuximab in combination with chemotherapy in first-line setting in Stage IIIb/IV NSCLC
Author Phase n Chemotherapya Results for cetuximab group
Thienelt et al77 I/IIa 31 Cb AUC 6  
T 225 mg/m2  
(every 3 wk)
Median OS 11 mos  
Median TTP 5 mos
robert et al78 I/IIa 35 Cb AUC 5  
Gem 1000 mg/m2(d1,8) (every 3 wk)
Median OS 320 days  
Median TTP 165 days
Butts et al79 ii 131 Cb AUC 5 or CDDP 75 mg/m2  
Gem 1000 mg/m2 (d1,8)  
(every 3 wk)
Median OS 11.99 mos  
Median PFS 5.09 mos
Spigel et al80 ii 27 Gem 1000 mg/m2 iv  
Doc 30 mg/m2 iv days 1, 8  
(every 3 wk)
Median OS Nr  
Median PFS Nr
Belani et al81 ii 80 Cb AUC 6  
Docetaxel 75 mg/m2  
(every 3 wk)
Median OS 10.3 mos  
Median PFS 4.6 mos
Borghaei et al82 ii 53 Cb AUC 6  
T 100 mg/m2 (d1,8,15)  
(every 4 wk)
Median OS 13.8 mos  
Median TTP 5.5 mos
Bradford et al85 ii 57 Cb AUC 6 Pending
Lilenbaum et al86 
(PS 2 patients)
ii 55 Doc (30 mg/m2 wkly for 3 wk) or  
Bortezomib (1.6 mg/m2 wkly for 3 wk)  
(every 4 wk)
Median OS 3.8 vs 3.3 mos  
Median PFS 3.1 vs 1.8 mos
rosell et al87 ii 86 CDDP 80 mg/m2  
Vinorlebine 25 mg/m2 (d1,8)  
(every 3 wk)
Median OS 8.3 mos  
Median PFS 5 mos
Pirker et al71,88 iii 1125 CDDP 80 mg/m2  
Vinorlebine 25 mg/m2 (d1,8)  
(every 3 wk)
Median OS 11.3 mos  
Median PFS Nr
Lynch et al89 iii 676 Cb AUC 6 with  
T (225 mg/m2 )  
or  
Dose (75 mg mg/m2)  
(every 3 wk)
Median OS Nr  
Median PFS 4.4 mos
aAll evaluated chemotherapy in addition to cetuximab (400 mg/m2 iv during the first week followed by 250 mg/m2 iv weekly) unless otherwise specified.
Abbreviations: Cb, carboplatin;   T, paclitaxel; CDDP, cisplatin; Gem, gemcitabine;   AUC, area under the curve; Doc, docetaxel; OS, overall survival; PFS, progression-free survival; 
mos, months; wk, weeks; Nr, not reported; TTP, time to progression.OncoTargets and Therapy 2009:2 255
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were 40% and 16%, respectively. Pharmacokinetic sampling 
did not reveal an interaction between carboplatin, paclitaxel, 
and cetuximab.
In another similar phase I/II study, Robert et al evaluated 
the use of cetuximab in combination with carboplatin and 
gemcitabine in previously untreated, advanced NSCLC 
patients.78 All tumors were positive for EGFR receptor by 
IHC (1+). Thirty-five patients received treatment with 
cetuximab with standard dosing. Carboplatin (AUC 5, 
day 1) and gemcitabine 1000 mg/m2 on days 1 and 8 were 
administered every 3 weeks. Responses included 10 partial 
responses (PR) (28.6%). Twenty-one patients had stable 
disease (SD). The median TTP was 165 days, and the median 
overall survival (OS) was 310 days. Butts et al randomized 
65 patients with advanced metastatic NSCLC in a phase II 
study to receive gemcitabine (1250 or 1000 mg/m2 iv, days 1 
and 8) plus cisplatin (75 mg/m2 every 3 weeks) or carbo-
platin (AUC 5 every 3 weeks), with or without cetuximab 
in standard dosing.79 Median PFS and OS were marginally 
better in patients that received cetuximab (PFS: 5.09 vs 4.21 
months, OS: 11.99 vs 9.26 months). Spigel et al evaluated 
the combination of gemcitabine 1000 mg/m2 iv and docetaxel 
30 mg/m2 iv days 1, 8 in combination with standard dosing 
of cetuximab in newly diagnosed unresectable stage III/IV 
NSCLC.80 Twenty-seven patients were included in this analy-
sis (n = 66 planned). Accrual was temporarily suspended 
due to a higher than anticipated rate of cetuximab-based 
hypersensitivity reactions. Overall response rate (ORR) was 
13%, 9 patients (39%) had SD and 7 patients had progres-
sive disease.
Several phase II studies examined the role of maintenance 
cetuximab in addition to its use with upfront chemotherapy. 
Belani et al enrolled 80 previously untreated patients in a 
phase II study to receive standard doses of cetuximab plus 
docetaxel (at a dose of 75 mg/m2 on day 1) and carboplatin 
(AUC 6 on day 1) every 21 days for up to 6 cycles.81 
Thereafter, patients without evidence of disease progression 
were continued on single-agent cetuximab for a maximum of 
1 year or until disease progression. The objective response 
rate was 15.2%, with a median PFS of 4.6 months and 
a median OS of 10.3 months. Another similar phase II 
trial by Borghaei et al evaluated the use of standard doses 
of cetuximab in combination with monthly carboplatin 
(AUC 6 day 1) and weekly paclitaxel (100 mg/m2 days 1, 8, 
and 15) every 4 weeks.82 In patients without disease progres-
sion or limiting toxicity, cetuximab was continued as a single 
agent after 6 full cycles of therapy (28% of the patients). 
Fifty-three patients were accrued. ORR was 57% and 23% 
had SD. Median TTP was 5.5 months, median survival 
was 13.8 months; 1-year OS 53%, 2-year OS 18%. Saleh 
et al evaluated two different schedules of chemotherapy 
administration in addition to standard doses of cetuximab.83 
Beginning on day 8, a schedule of iv carboplatin (AUC 6) and 
paclitaxel 225 mg/m2 given on a 3-week cycle was compared 
with a schedule of iv carboplatin (AUC 6) every 4 weeks and 
paclitaxel 100 mg/m2 weekly for 3 weeks of each 4-week 
cycle. Patients who achieved CR, PR, or SD after 4 cycles 
continued on weekly cetuximab monotherapy until disease 
progression or unacceptable toxicity. Cetuximab combined 
with chemotherapy in both dose schedules demonstrated 
activity and an acceptable toxicity profile. The Southwestern 
Oncology Group (SWOG) randomized untreated patients 
with advanced stage NSCLC to receive paclitaxel 225 mg/m2 
and carboplatin (AUC 6) every 3 weeks plus standard doses 
of cetuximab concurrently followed by maintenance cetux-
imab or sequential chemotherapy for 4 cycles followed 
by cetuximab.84 Treatment was continued until disease 
progression. Toxicities were significantly increased with 
concurrent therapy. A phase II trial of paclitaxel, carboplatin, 
cetuximab, and bevacizumab in this patient population is 
ongoing (SWOG 0536) in anticipation of a phase III trial. 
Carboplatin (AUC 6) every 3 weeks for 4 cycles (12 weeks) 
was used in combination with cetuximab in a phase II trial.85 
Final PFS and OS data are pending (Table 1).
Table 2 Trials evaluating the use of cetuximab with chemotherapy in relapsed/refractory in Stage IIIb/IV NSCLC
Author Phase n Treatment Results
Hanna et al90 ii 66 weekly cetuximab Orr 4.5%  
Median OS 8.9 mos  
Median TTP 2.3 mos
Jalal et al91 I/IIa 23 weekly cetuximab +  
Pem (750 mg/m2 iv every 3 weeks)
Orr 9.5%  
Median TTP 5.5 mos
Kim et al92 ii 47 weekly cetuximab +  
Doc (75 mg/m2 iv every 3 weeks)
Median TTP 89 days
Abbreviations: OS, overall survival;   TTP, time to progression;  Pem, pemetrexed;  Orr, overall response rate.OncoTargets and Therapy 2009:2 256
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Lilenbaum et al randomized untreated patients with 
advanced NSCLC and PS 2 to docetaxel (30 mg/m2 weekly 
for 3 weeks in a 28-day cycle) in combination with either 
cetuximab or bortezomib (1.6 mg/m2 weekly for 3 weeks in 
a 28-day cycle) for 4 cycles.86 Patients whose disease was 
controlled (CR/PR/SD) were allowed to continue cetuximab 
or bortezomib until progressive disease. Sixty-four patients 
were enrolled; median PFS was 3.1 months for cetuximab and 
1.8 months for bortezomib. Median survival was 3.8 months 
for cetuximab and 3.3 months for bortezomib.
In a randomized phase II study, Rosell et al randomized 
86 chemo-naive patients with advanced EGFR(1 + IHC) 
expressing NSCLC to every 3 weeks cisplatin (80 mg/m2, 
day 1) with vinorelbine (25 mg/m2 on days 1 and 8) with or 
without weekly cetuximab.87 Median PFS was higher for the 
cetuximab group (5.0 vs 4.6 months, hazard ratio 0.71). There 
was also a trend toward improved OS (8.3 vs 7.3 months, 
hazard ratio 0.71). The cetuximab combination was well 
tolerated. This combination was further validated in a 
prospective randomized phase III trial.71,88 Tumor samples 
from 1688 patients were analyzed. A total of 1125 patients 
with EGFR expressing tumors (1 + IHC) were randomized 
to the above combination. Primary endpoint was OS, and 
RR, PFS, disease control, and quality of life were secondary 
endpoints. Cetuximab was continued as maintenance 
therapy in the cetuximab arm until disease progression 
or unacceptable toxicity. The percentage of patients who 
received single-agent cetuximab and the duration of treatment 
with this agent were not reported. Addition of cetuximab was 
associated with a superior OS over chemotherapy alone in 
all patients with EGFR-detectable advanced NSCLC (median 
OS 11.3 vs 10.1 months, P = 0.0441). Even though the 
121 Asian patients enrolled in the study had prolonged OS 
compared to Caucasians (median OS 19.5 mos vs 9.6 mos), 
they did not achieve a survival benefit by addition of 
cetuximab to chemotherapy compared to chemotherapy alone 
(17.6 vs 20.4 months, P = 0.49). There was also no significant 
difference in PFS in the two treatment arms.
In another large phase III trial, Lynch et al randomized 
previously untreated stage IIIb/IV NSCLC patients to receive 
either paclitaxel (225 mg/m2 iv) or docetaxel (75 mg mg/m2 
iv) and carboplatin (AUC 6 iv) every 3 weeks with or without 
cetuximab.89 The choice of taxane was at the discretion of the 
investigator. A total of 676 six patients were randomized at 
97 centers in the United States. There were no statistically 
significant differences in PFS (4.4 vs 4.2 months, P = 0.23). 
ORR, however, was statistically significantly superior for the 
cetuximab arm (25.7% vs 17.2%, P = 0.0066).
Clinical efficacy in recurrent disease
Hanna et al evaluated single-agent cetuximab used at its 
standard dosing schedule in 66 recurrent NSCLC patients 
(60 EGFR positive by IHC), ORR was 4.5% and 30.3% of 
patients achieved SD. Median TTP and OS were 2.3 months 
and 8.9 months, respectively.90 ORR in the EGFR positive 
population was 5%. All three patients with CR had EGFR 
positive tumors. An exploratory analysis of EGFR mutational 
status was performed on 38 tumor specimens. Three patients 
had activating mutations (2 patients with SD, 1 PD).
Jalal et al evaluated the feasibility of combining pemetrexed 
and cetuximab in a phase I/IIa study, in patients with recurrent, 
previously treated NSCLC with 1 prior platinum containing 
regimen.91 Prior use of EGFR TKIs was permitted. Cetuximab 
was given at a standard dosing schedule. Pemetrexed, however, 
was administered at 750 mg/m2 iv every 3 weeks. After com-
pleting at least 4 cycles, patients with non-progressive disease 
were allowed to continue cetuximab alone until progression. 
PR was seen in 2 patient (8.7 %), 8 patients (34.8%) had SD. 
Median TTP was 5.5 mos. This combination resulted in longer 
time to progression when compared with historical controls 
of pemetrexed alone administered at a dose of 500 mg/m2 
every 21 days.
In a phase II trial by Kim et al 47 patients with refractory 
NSCLC or who had disease recurrence within 3 months after 
chemotherapy and tumor overexpression of EGFR of at least 
1+ by IHC received cetuximab with docetaxel (75 mg/m2 iv 
every 3 weeks).92 Thirteen patients (28%) achieved PR and 
8 (17%) had SD. Median TTP was 89 days.
Clinical efficacy in combination  
with radiation therapy
Cetuximab when added to radiation therapy (RT) statistically 
significantly improved median survival and loco regional 
control in treatment of locally advanced squamous cell car-
cinomas of the head and neck.93 Based on these encouraging 
results, a phase I study was designed to assess the safety 
of concomitant cetuximab and radical RT in patients with 
inoperable Stage III NSCLC.94 Patients received weekly iv 
cetuximab (in an initial dose of 400 mg/m2; maintenance 
dose 250 mg/m2) after platinum-based induction therapy and 
concomitant RT (64 Gy/32fractions/45 days). The results 
suggested that the early and late toxicities of concomitant 
cetuximab and radical RT were acceptable.
An ongoing radiation therapy oncology group (RTOG) 
trial, RTOG 0324, is evaluating the combination of 
cetuximab with RT in unresectable stage III NSCLC 
patients.95 Cetuximab in an initial dose of 400 mg/m2 iv is OncoTargets and Therapy 2009:2 257
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followed by weekly doses of 250 mg/m2 until completion 
of therapy. RT was started the week after loading dose 
(63 Gy/35 fractions) with weekly carboplatin (AUC 2) 
and paclitaxel (45 mg/m2 × 6 doses) to be followed by 2 
cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m2). 
An interim analysis showed improvement in OS compared 
to historical controls (response rate 62% (n = 54), median 
survival 22.7 monthss and 2-year OS of 49.3%).
The Cancer and Leukemia Group B (CALGB) is 
evaluating the combination of carboplatin (AUC 5) iv and 
pemetrexed (500 mg/m2) iv every 3 weeks with concurrent RT 
(70 Gy over 7 weeks) with or without the use of cetuximab 
followed by 4 cycles of consolidation with pemetrexed.96 
Early evaluation of this CALGB 30407 trial suggests that the 
combination of thoracic radiation with pemetrexed, carboplatin 
with or without cetuximab is feasible and is well tolerated.
Safety and tolerability
In phase I and II trials, cetuximab was safe and well tolerated. 
It has non-overlapping toxicities with most chemotherapy 
agents, making it an attractive agent to be incorporated 
into chemotherapy and radiation therapy regimens. In the 
phase I study dose finding trial, 5 episodes of grade 3 or 
higher toxicity were seen. Toxicity was not related to dose 
level or number of cycles administered and most common 
drug related adverse effects were fevers, chills, asthenia, 
transaminitis, and skin toxicity.45
Acneiform rash is one of the most common toxicities 
seen with cetuximab use and occurs in approximately 90% 
of treated patients at different grades.97 There seems to be a 
higher response rate in patients in whom cetuximab induces 
a rash than in cetuximab-treated patients who do not experi-
ence a rash. Rash therefore could be a surrogate marker for 
response.98 Cetuximab-induced rash is manageable with the 
use of topical steroids, topical antibiotics, topical emollients, 
oral antibiotics, and dose modifications.99–104
Other toxicities with cetuximab include infusion-related 
hypersensitivity reactions, which have been associated with 
the presence of an IgE antibody against glycosylation sites 
on cetuximab.105,106 These reactions were more common in 
patients with prior allergy history and are less commonly seen 
with panitumumab, which is a fully human IgG2 antibody. 
Hypomagnesemia is a class effect of EGFR inhibitors and 
is commonly seen with use of cetuximab.107,108
Conclusions
The EGFR receptor is often overexpressed in NSCLCs, 
making cetuximab an attractive drug. Cetuximab is fairly well 
tolerated overall and has an acceptable safety and manageable 
tolerability profile.
In the first-line setting, most phase II studies suggest that 
adding cetuximab to platinum-based therapies is of clinical 
benefit. A recently reported phase III trial demonstrated a modest 
OS benefit when cetuximab was added to cisplatin and vinorel-
bine in the first-line treatment of NSCLC.71 In a second phase 
III trial, addition of cetuximab to carboplatin and a taxane gave 
only a marginal additional PFS benefit.89 Despite this improve-
ment, there are still some unanswered questions, mainly in terms 
of patient selection. Optimal selection of patients who would 
benefit from cetuximab is challenging and is key in its further 
development as a therapeutic agent in lung cancer. The role of 
predictive markers like EGFR amplification by FISH, KRAS 
mutation are being explored and larger prospective studies are 
needed before they can be routinely used in clinical practice.
Combination studies with other targeted agents, especially 
vascular endothelial growth factor antagonist, are being explored. 
Ongoing studies are also evaluating the role of cetuximab in 
combination with radiation with or without chemotherapy109 in 
locally advanced unresectable NSCLC. While final results are 
pending, interim analyses reveal that cetuximab is feasible and 
safe to use with radiation in this patient population.
Cetuximab adds to our arsenal of drugs and represents 
an improvement in survival outcomes in patients with 
NSCLC. In upcoming years we anticipate more clinical trials 
combining cetuximab with new targeted treatments which 
will hopefully improve outcomes while minimizing toxicity.
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